new technologies competing with glp-1 medications 2025 A second helping of weight-loss drugs is coming Outlook for obesity in 2025:

The strategy of using GLP-1 analogs for diabetes therapy has the advantage over pharmacological DPP-IV inhibition that it is highly specific and does not lead to ubiquitous inhibition of the degradation of multiple regulatory peptides

Known for being gentle, it suits people who want muscle gains but dont want bloating or hunger swings

Accumulation of SnCs during aging is due to the decrease of immune surveillance, probably related to dysregulation of pathways involved in the immune system activation 41,42

A tailwind for the cosmetics and beauty industry: Skincare products and treatments that support firmness, face contouring, and body sculpting will see growth from the increasing number of GLP-1 users who are losing weight and find that their skin needs support during the weight loss transition and thereafter